Cardiol Therapeutics Inc. is a company that focuses on developing anti-inflammatory and anti-fibrotic therapies for cardiovascular disease treatment. Its lead product, CardiolRx, is currently undergoing a Phase II/III study to test effectiveness in reducing COVID-19-related cardiovascular and respiratory events. Additionally, the company is developing a subcutaneous formulation of CardiolRx for the treatment of heart failure-related fibrosis and inflammation.